Inovio Pharmaceuticals, INC.: management transactions · United States · SEC (Form 4)

About Inovio Pharmaceuticals, INC.

INOVIO PHARMACEUTICALS, INC. (NASDAQ: INO) is a U.S.-listed biotechnology company headquartered in Plymouth Meeting, Pennsylvania, on the NASDAQ market in the United States. The company is focused on developing and commercializing DNA medicines, with a long-standing emphasis on HPV-related diseases, cancer, and infectious diseases. Its business model is centered on research and development, clinical execution, regulatory interaction with the FDA, and—if successful—eventual commercialization of its product candidates. ([inovio.com](https://www.inovio.com/?utm_source=openai)) Founded in the mid-2000s from technology built by its scientific founders, INOVIO was established around a proprietary DNA-medicine platform designed to trigger immune responses in the body. Over time, the company has evolved into a classic clinical-stage biotech: highly innovative, but still dependent on trial outcomes, regulatory milestones, and capital markets access. That platform-based strategy allows INOVIO to pursue multiple indications using a common scientific architecture, while also exposing the business to the usual biotech risks—clinical uncertainty, development delays, capital needs, and dilution risk from financing activity. ([inovio.com](https://www.inovio.com/?utm_source=openai)) In terms of business lines, INOVIO is primarily developing DNA-based vaccine and immunotherapy candidates. The most closely watched program today is INO-3107, which is being developed for adults with recurrent respiratory papillomatosis. In 2025, the company said the FDA had accepted its BLA for review and assigned a PDUFA target action date of October 30, 2026, making this one of the key regulatory catalysts for the stock. INOVIO continues to present its pipeline at scientific conferences and provide periodic updates on its development priorities and business progress. ([ir.inovio.com](https://ir.inovio.com/news/news-details/2025/FDA-Accepts-for-Review-INOVIOs-BLA-for-INO-3107-for-the-Treatment-of-Adults-with-Recurrent-Respiratory-Papillomatosis-RRP/default.aspx?utm_source=openai)) From a competitive standpoint, INOVIO operates in a crowded global biotech landscape that includes large pharmaceutical companies, specialist immunotherapy developers, and alternative vaccine-platform companies. Its main differentiator is its DNA-medicine technology and its focus on niche disease areas with significant unmet medical need. However, the company remains constrained by its clinical-stage profile, limited recurring revenue base, and reliance on successful execution in trials and regulatory reviews. Geographically, the company is rooted in the United States, but its development history, collaborations, and conference activity give it an international reach. Recent highlights include continued regulatory progress for INO-3107, several 2025–2026 financial updates, and capital-raising efforts aimed at funding the next stages of development. ([ir.inovio.com](https://ir.inovio.com/news/news-details/2026/INOVIO-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Business-Highlights/default.aspx?utm_source=openai))